ANRO Stock Analysis: Alto Neuroscience | NYSE
Biotechnology | NYSE, USA | Market Cap: 1.395m USD | 12M Return: 820.6% | US02157Q1094 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 14.2M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 2.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Alto Neuroscience (NYSE: ANRO) is a U.S.-based clinical-stage biopharmaceutical company developing small-molecule therapies for central nervous system (CNS) disorders. The company is headquartered in Mountain View, California, and was incorporated in 2019 before completing its IPO in February 2024.
Its pipeline is focused on depression, schizophrenia, and Parkinsons disease. Lead candidate ALTO-100 is in a Phase 2b trial for bipolar depression. ALTO-300 (a melatonergic agonist/serotonergic antagonist) is in a Phase 2b trial for major depressive disorder (MDD). Additional programs include ALTO-101 (PDE4 inhibitor) for cognitive impairment in schizophrenia, ALTO-203 (H3 receptor inverse agonist) for MDD with anhedonia, ALTO-202 (GluN2B NMDA receptor antagonist) in Phase 1 for MDD, and ALTO-208, a fixed-dose combination of pramipexole and aprepitant for Parkinsons disease.
As a clinical-stage biopharmaceutical company, Alto Neuroscience does not yet generate commercial product revenue and is dependent on external capital, including proceeds from its 2024 IPO, to fund ongoing trials. CNS drug development is characterized by long development timelines, high rates of clinical failure, and significant reliance on a small number of lead programs to drive long-term value.
- ALTO-100 Phase 2b results in bipolar depression due
- ALTO-300 Phase 2b readout in major depressive disorder
- Cash burn raises dilution risk as pipeline advances
- Schizophrenia competitor approvals pressure ALTO-101 outlook
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.27 > 0.02 and ΔFCF/TA 8.77 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.27 > 3% & CFO -68.3m > Net Income -84.2m |
| Net Debt (-220.4m) to EBITDA (45.1m): -4.88 < 3 |
| Current Ratio: 14.85 > 1.5 & < 3 |
| Outstanding Shares: last quarter (42.8m) vs 12m ago 58.14% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.25%; Δ -0.25% > 0%) |
| Interest Coverage Ratio: 19.66 > 6 (EBIT TTM 44.5m / Interest Expense TTM 2.26m) |
| A: 0.91 (Total Current Assets 247.3m - Total Current Liabilities 16.7m) / Total Assets 254.1m |
| B: -1.01 (Retained Earnings -255.5m / Total Assets 254.1m) |
| C: 0.22 (EBIT TTM 44.5m / Avg Total Assets 206.0m) |
| D: 6.30 (Book Value of Equity 219.2m / Total Liabilities 34.8m) |
| Altman-Z'' = 10.74 = AAA |
As of September 09, 2026, the stock is trading at USD 35.81 with a total of 580,709 shares traded. Over the past week, the price has changed by +1.22%, over one month by +26.58%, over three months by +96.33% and over the past year by +820.57%.
Current recommended Stop Loss: 33.40 (which is 6.7% or 1.3 ATR below the current price).
Alto Neuroscience has received a consensus analysts rating of 4.63. Therefore, it is recommended to buy ANRO.
- StrongBuy: 6
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 38.4 | 7.2% |
P/B = 6.515
Revenue TTM = 0.0 USD
EBIT TTM = 44.5m USD
EBITDA TTM = 45.1m USD
Long Term Debt = 14.9m USD (from longTermDebt, last quarter)
Short Term Debt = 3.77m USD (from shortTermDebt, last quarter)
Debt = 23.3m USD (corrected: LT Debt 14.9m + ST Debt 3.77m) + Leases 4.64m
Net Debt = -220.4m USD (calculated: Debt 23.3m - CCE 243.7m)
Enterprise Value = 1.17b USD (1.40b + Debt 23.3m - CCE 243.7m)
Interest Coverage Ratio = 19.66 (Ebit TTM 44.5m / Interest Expense TTM 2.26m)
EV/FCF = -17.06x (Enterprise Value 1.17b / FCF TTM -68.8m)
FCF Yield = -5.86% (FCF TTM -68.8m / Enterprise Value 1.17b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 661k) / Revenue TTM)
Tobins Q-Ratio = 4.62 (Enterprise Value 1.17b / Total Assets 254.1m)
Interest Expense / Debt = 9.71% (Interest Expense 2.26m / Debt 23.3m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 35.1m (EBIT 44.5m * (1 - 21.00%))
Current Ratio = 14.85 (Total Current Assets 247.3m / Total Current Liabilities 16.7m)
Debt / Equity = 0.11 (Debt 23.3m / totalStockholderEquity, last quarter 219.2m)
Debt / EBITDA = -4.88 (Net Debt -220.4m / EBITDA 45.1m)
Debt / FCF = 3.20 (negative FCF - burning cash) (Net Debt -220.4m / FCF TTM -68.8m)
Total Stockholder Equity = 181.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -40.90% (Net Income -84.2m / Total Assets 254.1m)
RoE = -46.46% (Net Income TTM -84.2m / Total Stockholder Equity 181.3m)
RoCE = 22.66% (EBIT 44.5m / Capital Employed (Equity 181.3m + L.T.Debt 14.9m))
RoIC = 14.56% (NOPAT 35.1m / Invested Capital 241.2m)
WACC = 8.54% (E(1.40b)/V(1.42b) * Re(8.55%) + D(23.3m)/V(1.42b) * Rd(9.71%) * (1-Tc(0.21)))
Discount Rate = 8.55% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 74.97 | Cagr: 22.97%
[DCF] Fair Price = unknown (Cash Flow -68.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.40 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.70 | Chg30d=+11.95% | Revisions=+50% | Analysts=7
EPS current Year (2026-12-31): EPS=-2.92 | Chg30d=+7.10% | Revisions=+50% | GrowthEPS=+0.0% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-3.29 | Chg30d=+4.30% | Revisions=+40% | GrowthEPS=-12.5% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +73% (up=8, down=0)